Dallas Diabetes and Endocrine Center
Welcome,         Profile    Billing    Logout  
 15 Trials 
35 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Coates, Allan
COMPASS-CD, NCT04809363: A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Active, not recruiting
4
200
US
CDPATH™, PROSPECT, Blood Draw
Takeda
Crohn's Disease
08/23
06/26
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NAVIGATE, NCT04365868: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc.
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
NCT05019742: Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis

Recruiting
2
30
US
SPH3127, Placebo
Shanghai Pharma Biotherapeutics USA Inc.
Ulcerative Colitis
12/25
12/25
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
140
Europe, US, RoW
Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
12/27
09/28
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/25
11/25
NCT04607746: Pivotal Study of the CapsoCam Colon (CV-3) in Detecting Colonic Polyps, Using Colonoscopy as the Reference

Recruiting
N/A
1200
US
Capsule Endoscope
Capso Vision, Inc.
Colonic Polyp
12/24
12/24
Rosenstock, Julio
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
ACHIEVE-2, NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

Recruiting
3
888
Europe, US, RoW
Orforglipron, LY3502970, Dapagliflozin
Eli Lilly and Company
Type 2 Diabetes
10/25
10/25
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
12/26
03/27
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed
3
692
Europe, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Type 1 Diabetes, Diabetes
05/24
05/24
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
795
US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, T2D
07/24
07/24
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Active, not recruiting
3
700
US
Tirzepatide, LY3298176, Semaglutide
Eli Lilly and Company
Obesity, Overweight
11/24
11/24
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Active, not recruiting
3
520
Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
04/25
04/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
08/25
08/25
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
NCT06047548: A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
400
US
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Overweight, Obesity
05/26
05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
765
US
LY3305677, LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
LEGEND, NCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Completed
2
42
Europe, US
IVA337, Lanifibranor, Placebo, Empagliflozin, Jardiance
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
03/24
06/24
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
250
US
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
06/25
09/25
NCT06373146: A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Recruiting
2
360
US, RoW
Tirzepatide, LY3298176, Mibavademab, REGN4461, Tirzepatide-Placebo, Mibavademab-Placebo
Eli Lilly and Company, Regeneron Pharmaceuticals
Obesity
12/25
04/26
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo

Recruiting
2
120
US
Nimacimab injection, Nimacimab placebo injection, semaglutide injection
Skye Bioscience, Inc., Bird Rock Bio Sub, Inc.
Obesity
08/25
01/26
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06124807: A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
165
US
LY3305677, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
11/24
05/25
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/25
11/25
Barritt, Alfred S
NAVIGATE, NCT04365868: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc.
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/25
11/25
HORIZON, NCT05583344: Phase 2b Study of GSK4532990 in Adults With NASH

Recruiting
2
246
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Nonalcoholic Fatty Liver Disease
09/25
12/25

Download Options